



Medicare Part B Prescription Drugs – Step Therapy

Starting **July 1, 2026**, Step Therapy will be required for the non-preferred drugs listed in the table below. These requirements are in addition to the Step Therapy requirements which went into effect on January 1, 2026. Part B Step Therapy Preferred Drug list applies to all SCAN plans in California and SCAN Embrace (HMO POS I-SNP), SCAN Embrace Together (HMO POS I-SNP) in Maricopa and Pima Counties. This list is subject to change. To see the most up-to-date information, please visit [SCAN Prior Authorization Requirements](#) and [SCAN Prior Authorization Requirement Changes Effective 7/1/2026](#).

Therapeutic Class	Effective Date	Preferred	Non-Preferred
Bevacizumab for cancer BCG0318 Part B Step Therapy Criteria for Bevacizumab Products	1/1/2026	Alymsys (Q5126) Mvasi (Q5107) Zirabev (Q5118)	Avastin (J9035) Vegzelma (Q5129)
Granulocyte Colony Stimulating Factors (G-CSF), Long-Acting (Pegfilgrastim to boost white blood cells) BCG0320 Part B Step Therapy Criteria for Long-Acting G-CSF	1/1/2026	Fulphila (Q5108) Nyvepria (Q5122) Udenyca (Q5111)	Fylnetra (Q5130) Neulasta (J2506) Neulasta Onpro (J2506) Rolvedon (J1449) Stimufend (Q5127) Ziextenzo (Q5120)
Granulocyte Colony Stimulating Factors (G-CSF), Short-Acting (Filgrastim to boost white blood cells) BCG0319 Part B Step Therapy Criteria for Short Acting G-CSF	1/1/2026	Nivestym (Q5110) Releuko (Q5125)	Granix (J1447) Neupogen (J1442) Nypozi (Q5148) Zarxio (Q5101)
Immunoglobulin, intravenous (IVIG) for immune deficiency or neurological disorders BCG0317 Part B Step Therapy Criteria for Intravenous Immunoglobulin IVIG	1/1/2026	Gammagard (J1569) GamunexC (J1561)	Alyglo (J1552) Asceniv (J1554) Bivigam (J1556) Gammaplex (J1557) Octagam (J1568) Panzyga (J1576) Privigen (J1459)
Immunoglobulin, subcutaneous (SCIG) for immune deficiency or neurological disorders BCG0316 Part B Step Therapy Criteria for Subcutaneous Immunoglobulin (SCIG)	1/1/2026	Cutaquig (J1551) Hizentra (J1559) Xembify (J1558)	Cuvitru (J1555) HyQvia (J1575)
Infliximab for autoimmune diseases BCG0313 Part B Step Therapy Criteria for Infliximab Products	1/1/2026	Avsola (Q5121) Inflectra (Q5103)	Remicade (J1745) Renflexis (Q5104)
Osteoporosis Treatments BCG0311 Part B Step Therapy Criteria for Evenity	1/1/2026	Zoledronic acid (J3489) Jubbonti (Q5136) Prolia (J0897)	Evenity (J3111)
Rituximab for cancer and autoimmune diseases BCG0314 Part B Step Therapy Criteria for Rituximab Products	1/1/2026	Riabni (Q5123) Ruxience (Q5119) Truxima (Q5115)	Rituxan (J9312) Rituxan Hycela (J9311)
Trastuzumab for Cancer BCG0312 Part B Step Therapy Criteria for Trastuzumab Products	1/1/2026	Kanjinti (Q5117) Ogivri (Q5114) Ontruzant (Q5112) Trazimera (Q5116)	Herceptin (J9355) Herceptin Hylecta (J9356) Hercessi (Q5146) Herzuma (Q5113)

Vascular Endothelial Growth Factor (VEGF) Inhibitors for macular degeneration and other eye conditions BCG0315 Part B Step Therapy Criteria for Ophthalmologic VEGF Inhibitors	1/1/2026	Bevacizumab, Intravitreal Inj (C9257, J9035), then Beovu (J0179) Byooviz (Q5124), Eylea (J0178) Eylea HD (J0177)	Cimerli (Q5128) Lucentis (J2778) Pavblu (Q5147) Susvimo (J2779) Vabysmo (J2777)
Anti-CD20 monoclonal antibody for Multiple Sclerosis Part B Step Therapy Criteria for monoclonal antibody for Multiple Sclerosis	7/1/2026	Briumvi (J2329) Ocrevus (J2350) Ocrevus Zunobo (J2351)	Lemtrada (J0202) Tysabri (J2323) Tyruko (Q5134)
Anti-integrin monoclonal antibody ($\alpha 4\beta 7$ inhibitor) for Inflammatory Bowel Disease (IBD) Part B Step Therapy Criteria for Selective Adhesion-Molecule Inhibitors for Inflammatory Bowel Disease (IBD)	7/1/2026	Entyvio (J3380)	Tysabri (J2323) Tyruko (Q5134)
Antifolate Antimetabolite (pemetrexed) for Non-Small Cell Lung Cancer (NSCLC) Part B Step Therapy Criteria for Antifolate Antimetabolite (pemetrexed) for Non-Small Cell Lung Cancer (NSCLC)	7/1/2026	Generic Alimta (J9305) pemetrexed Accord (J9296) pemetrexed ditromethamine (J9323) pemetrexed Hospira (J9294) pemetrexed Sandoz (J9297) pemetrexed Teva (J9314)	Axtle (J9292) Pemfexy (J9304) Pemrydi RTU (J9324)
Botulinum Toxins A and B Part B Step Therapy Criteria for Botulinum Toxins A and B	7/1/2026	Cervical Dystonia: Daxxify (J0589) Myobloc (J0587) Xeomin (J0588) Sialorrhea: Myobloc (J0587) Spasticity: Xeomin (J0588)	Botox (J0585) Dysport (J0586)
C1 inhibitors for Hereditary Angioedema – Acute Part B Step Therapy Criteria for C1 inhibitors for Hereditary Angioedema – Acute	7/1/2026	Icatibant acetate, generic (J1744)	Berinert (J0597) Kalbitor (J1290) Ruconest (J0596)
C1 inhibitors for Hereditary Angioedema – Prophylaxis Part B Step Therapy Criteria for C1 inhibitors for Hereditary Angioedema – Prophylaxis	7/1/2026	Cinryze IV (J0598) Haegarda IV (J0599) Takhzyro (J0593)	Dawnzera (J3590)
Complement C5 inhibitors and FcRn antagonists for Myasthenia Gravis Part B Step Therapy Criteria for Complement C5 inhibitors and FcRn antagonists for Myasthenia Gravis	7/1/2026	Epysqli (Q5151) Uplizna (J1823) Vyvgart (J9332) Vyvgart Hytrulo (J9334)	Bkemv (Q5152) Imaavy (J9256) Rystiggo (J9333) Soliris (J1299) Ultomiris (J1303)
Complement inhibitors for Atypical Hemolytic Uremic Syndrome (aHUS), Paroxysmal Nocturnal Hemoglobinuria (PNH), and Neuromyelitis Optica Spectrum Disorder (NMOSD) Part B Step Therapy Criteria for Complement inhibitors for aHUS, PNH, and NMOSD	7/1/2026	aHUS: Epysqli (Q5151) Ultomiris IV (J1303) NMOSD: Epysqli (Q5151) Ultomiris IV (J1303) Uplizna (J1823) PNH: Epysqli (Q5151) Ultomiris IV (J1303)	Bkemv IV (Q5152) Soliris (J1299)

Erythropoiesis-Stimulating Agents (ESA) for non-dialysis dependent anemia Part B Step Therapy Criteria for Erythropoiesis Stimulating Agents (ESA) for non-dialysis dependent anemia	7/1/2026	Retacrit (Q5106) Procrit/Epogen (J0885)	Aranesp (J0881) Mircera (J0888)
Factor VIII products and Bispecific Factor IX and X for Hemophilia A without inhibitors Part B Step Therapy Criteria for Factor VIII products and Bispecific Factor IX and X for Hemophilia A without inhibitors	7/1/2026	Advate/Recombinate (J7192) Afstyla (J7210) Alphanate (J7186) Koate (J7190) Nuwiq (J7209) Xyntha (J7185)	Alhemo (J7173) Altuviiio (J7214) Adynovate (J7207) Alprolix (J7201) Eloctate (J7205) Esperoct (J7204) Hemlibra (J7170) Hympavzi (J7172) Jivi (J7208) Kovaltry (J7211) Novoeight (J7182) Qfitlia (J7174)
Folate analog for chemoprotectant & rescue therapy Part B Step Therapy Criteria for Leucovorin/Levoleucovorin	7/1/2026	Leucovorin calcium (J0640) Generic Levoleucovorin (J0641)	Khapzory (J0642)
Hyaluronic acids (viscosupplementation) for osteoarthritis of the knee Part B Step Therapy Criteria for Hyaluronic acids (viscosupplementation) for osteoarthritis of the knee	7/1/2026	Single Dose: Durolane (J7318) Synvisc One (J7325) Multi-Dose: Hyalgan (J7321) Euflexxa (J7323) Supartz (J7321) Synvisc (J7325) Trivisc (J7329) Visco-3 (J7333)	Single Dose: Gel-One (J7326) Hymovis One (J7322) Monovisc (J7327) Multi-Dose: Gelsyn (J7328) Genvisc (J7320) Hymovis (J7322) Orthovisc (J7324) Triluron (J7332)
Interleukins (IL-6) inhibitors for RA and neuromyelitis optica (Tocilizumab and biosimilars) Part B Step Therapy Criteria for Actemra and Tocilizumab Biosimilars	7/1/2026	Avtozma IV (Q5156) Tyenne IV (Q5135)	Actemra IV (J3262) Tofidence IV (Q5133)
Parenteral iron replacement therapy Part B Step Therapy Criteria for Parenteral iron replacement therapy	7/1/2026	Ferrlicit (J2916) Infed (J1750) Venofer (J1756)	Feraheme (Q0138) Injectafer (J1439) Monoferric (J1437)
Monoclonal antibody for severe eosinophilic asthma Part B Step Therapy Criteria for Severe Eosinophilic Asthma	7/1/2026	Cinqair IV (J2786) Fasenra prefilled syringe (J0517) Xolair vial (J2357)	Exdensur (J3590) Nucala vial (J2182) Tezspire vial or pre-filled syringe (J2356)
Monoclonal antibody for systemic lupus erythematosus (SLE) Part B Step Therapy Criteria for Monoclonal antibody for systemic lupus erythematosus (SLE)	7/1/2026	Benlysta IV (J0490)	Saphnelo (J0491)
PD-1 inhibitors for Head and Neck Cancer Part B Step Therapy Criteria for PD 1 inhibitors for Head and Neck Cancer	7/1/2026	Loqtorzi (J3263)	Keytruda (J9271) Keytruda Qlex (J3590/C9399) Opdivo (J9299) Opdivo Qvantiq (J9289)

<p>PD-1 inhibitors for non-small cell lung cancer (NSCLC) Part B Step Therapy Criteria for PD 1 inhibitors for non-small cell lung cancer (NSCLC)</p>	7/1/2026	<p>Libtayo (J9119) Keytruda (J9271) Keytruda Qlex (J3590/C9399) Tecentriq (J9022) Tecentriq Hybreza (J9024)</p>	<p>Imfinzi (J9173) Imjudo (J9347) Opdivo (J9299) +Yervoy (J9228) Opdivo Qvantiq (J9289) +Yervoy (J9228)</p>
<p>RANK-L inhibitors for oncologic indications Part B Step Therapy Criteria for RANK L inhibitors for oncologic indications</p>	7/1/2026	<p>Step1: Pamidronate (J2320), or Zoledronic Acid (J3489) Then, Step 2: Bomynta (Q5158) Wyost (Q5136) Xgeva (J0897) Xtrenbo (J3590)</p>	<p>Aukelso (J0897) Bilprevda (J3590) Osenvelt (Q5157) Xbryk (Q5159)</p>
<p>siRNA therapy (TTR silencing) for hereditary ATTR-PN amyloidosis Part B Step Therapy Criteria for siRNA therapy (TTR silencing) for hereditary ATTR PN amyloidosis</p>	7/1/2026	Amvuttra (J0225)	Onpattro (J0222)
<p>Somatostatin analogs Part B Step Therapy Criteria for Somatostatin analogs</p>	7/1/2026	Somatuline depot (J1930)	<p>Octreotide acetate depot/Sandostatin/ Sandostatin LAR (J2353) Signifor/Signifor LAR (J2502)</p>